Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer On Reorganizing, M&A And Investing In Internal R&D

Executive Summary

The big pharma's leadership weighs in on why it made sense to organize biosimilars under innovative medicines, why it is investing more in internal R&D, and why tuck-in deals are more appealing than transformative M&A.

You may also be interested in...

Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches

Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.

Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar

The latest drug development news and highlights from our US FDA Performance Tracker.

Pfizer Biosimilars And Anti-Infectives Get Higher Profile Under New Structure

Pfizer will reorganize from two business units to three, creating a separate Consumer Healthcare unit alongside Innovative Medicines and Established Medicines. The changes will not be effective until the beginning of 2019.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts